BioNTech Results Presentation Deck

Oncology Pipeline: Significant Progress and Expansion in 2022 Drug class Platform mRNA Cell therapies Antibodies SMIM 17 Fix Vac iNeST RiboMabs RiboCytokines Adjuvant pancreatic ductal adenocarcinoma¹ Intratumoral immunotherapy SAR441000 (BNT131)³ Solid tumors (IL-12sc, IL 15-sushi, GM-CSF, IFNa) BNT141 Multiple solid tumors (CLDN 18.2) BNT142 BNT151 Multiple solid tumors (CD3×CLDN6) Multiple solid tumors (optimized IL-2) Multiple solid tumors (IL-7, IL-2) BNT 152, BNT153 BNT211 Multiple solid tumors (CLDN6) BNT212 Pancreatic, other cancers (CLDN 18.2) Multiple solid tumors BNT221 (NEO-PTC-01) To be selected CAR T cells + CARVac Neoantigen-based T cells TCR engineered T cells Next-gen immune checkpoint modulators Product candidate BNT111 BNT112 BNT113 BNT 1151 BNT116 Targeted cancer antibodies Toll-like receptor binding Autogene cevumeran (BNT122)² Indication (targets) Advanced and R/R melanoma Prostate cancer HPV16+ head and neck cancer Ovarian cancer NSCLC 1L melanoma Adjuvant colorectal cancer Solid tumors GEN1046 (BNT311)4 GEN 1042 (BNT312)4 GEN1053 (BNT313)4 BNT321 (MVT-5873) BNT411 All tumors Metastatic NSCLC (PD-L1x4-1BB) Multiple solid tumors (PD-L1x4-1BB) Multiple solid tumors (CD40x4-1BB) Malignant solid tumors (CD27) Pancreatic cancer (sLea) Solid tumors (TLR7) SMIM, small molecule immunomodulators. 1 Investigator-initiated Phase 1 trial; 2 Collaboration with Genentech; 3 Collaboration with Sanofi; 4 Collaboration with Genmab. Pre-clinical Phase 1 Phase 2 Phase 3 [['|'|'||| Milestones FPD in July 2022 Data update: 1H 2023 FPD in Jan. 2022 FPD in July 2022 Data update: 2H 2022 Start Phase 1: 2H 2022 BIONTECH

View entire presentation